What an OHSU study found three months after one Oregon psilocybin session

A new OHSU-led study in JAMA Network Open (August 2026) followed 346 people after a single session at Oregon’s licensed psilocybin service centers.

This page summarizes the published findings for educational purposes. It is not medical advice, and it is not a claim that Lotus Mind Medicine operates Oregon licensed centers.


The findings at three months

One legal Oregon psilocybin session. Three months later, an OHSU-led study of 346 clients at Oregon’s licensed psilocybin centers (24 of 26 centers; the OPEN cohort) tracked moderate-to-severe symptoms before a session and again at 3 months:

  • Depression: 42% → 17% (60% drop)
  • Anxiety: 45% → 13% (71% drop)
  • PTSD: 48% → 17% (65% drop)

Also reported: life satisfaction 63% → 82%; 92% said they benefited; 1.2% had serious behavioral reactions.

How to read these results


Important context:

  • There was no control group, so this is not causal proof.
  • Participants opted in.
  • Oregon’s licensed nonmedical program did not require a diagnosis or a prescription.
  • Psilocybin is not FDA-approved.
  • Individual results vary.

This was an observational study. At Lotus Mind Medicine we follow research carefully—and keep claims honest.

A note from Lotus Mind Medicine

Lotus Mind Medicine tracks emerging research and keeps expectations honest. Preparation, screening, and integration matter as much as any molecule.

If you would like to learn more about our approach, visit lotusmindmedicine.com or request a free consult.

Educational only. Not medical advice.


Lotus Mind Medicine

Christian Lé, MD